杆菌的蛋白质CagA是一种强效和广泛的粉样蛋白抑制剂
Zhen Jin1, William Pallisgaard Olsen2, Cecilia Mörman1,3
1Department of Medicine, Huddinge, Karolinska Institutet, 14183 Huddinge, Sweden.
Science advances
|June 11, 2025
概括
杆菌释放CagA蛋白质,抑制细菌生物膜和致病性粉样蛋白形成. 这一发现为抗击细菌感染和人类蛋白质错折疾病提供了新的策略.
科学领域:
- 微生物学 微生物学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 细菌是影响人类健康的丰富生命形式.
- 杆菌与胃肠道疾病和其他疾病有关.
- 蛋白质聚合与各种人类疾病有关.
研究的目的:
- 研究Helicobacter pylori蛋白CagA在调节蛋白质组装中的作用.
- 确定CagA对细菌生物膜和人类粉样蛋白形成的影响.
- 探索CagA.的潜在治疗应用.
主要方法:
- 研究了CagA与蛋白纤维素形成的相互作用.
- 评估了CagA对细菌生物膜组装的抑制作用.
- 在人类疾病模型中分析了CagA对致病性粉样蛋白形成的影响.
主要成果:
- 杆菌会释放出CagA蛋白质. 在这种情况下,杆菌会释放出CagA蛋白.
- CagA强烈抑制了细菌生物膜的形成.
- 此外,CagA还可以抑制致病性粉样蛋白组合的形成.
- CagA表现出广泛的基质特异性,影响纤维形成的各个阶段.
结论:
- 杆菌的CagA蛋白质会干扰细菌和人类蛋白质的聚合.
- 这种机制为抗击细菌感染提供了新的方法.
- CagA为人类蛋白质错折疾病提供了潜在的治疗策略.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
335
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
335
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
358
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
358
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
100
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
100
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
545
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
545
Peptic Ulcer Disease IV: Management
78
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
78


